Aditxt’s (Nasdaq: ADTX) Adimune(TM) Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI(TM)-100 in Preparation for Planned Psoriasis First-in-Human Trials
We use cookies to improve your experience on our site, to show you personalized advertising, and as otherwise described in our Cookie Policy
. To find out more, read our
Privacy Policy
and our
Cookie Policy.